Editorial: COVID-19 booster vaccination: increasing immunity against life-threatening infection
Jazyk angličtina Země Švýcarsko Médium electronic-ecollection
Typ dokumentu úvodníky
PubMed
38264241
PubMed Central
PMC10804992
DOI
10.3389/fpubh.2023.1342118
Knihovny.cz E-zdroje
- Klíčová slova
- COVID-19, COVID-19 vaccination, SARS-CoV-2, booster vaccination, immune response, immunity, vaccines,
- MeSH
- COVID-19 * prevence a kontrola MeSH
- lidé MeSH
- sekundární imunizace MeSH
- vakcíny proti COVID-19 * aplikace a dávkování MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- úvodníky MeSH
- Názvy látek
- vakcíny proti COVID-19 * MeSH
Department of Public Health Faculty of Medicine Masaryk University Brno Czechia
Institute of Health Information and Statistics of the Czech Republic Prague Czechia
King Chulalongkorn Memorial Hospital Thai Red Cross Society Bangkok Thailand
Editorial on the Research Topic COVID-19 booster vaccination: increasing immunity against life-threatening infection PubMed
Zobrazit více v PubMed
Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, et al. . Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. (2022) 12:CD015477. 10.1002/14651858.CD015477 PubMed DOI PMC
Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte JM, Mak TM, et al. . Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect. (2022) 28:612.e1–612.e7. 10.1016/j.cmi.2021.11.010 PubMed DOI PMC
Castro Dopico X, Ols S, Loré K, Karlsson Hedestam GB. Immunity to SARS-CoV-2 induced by infection or vaccination. J Intern Med. (2022) 291:32–50. 10.1111/joim.13372 PubMed DOI PMC
McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al. . Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. (2022) 375:864–8. 10.1126/science.abn8652 PubMed DOI PMC
Jo N, Hidaka Y, Kikuchi O, Fukahori M, Sawada T, Aoki M, et al. . Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. Nat Aging. (2023) 3:82–92. 10.1038/s43587-022-00343-4 PubMed DOI PMC
Sourij C, Tripolt NJ, Aziz F, Aberer F, Forstner P, Obermayer AM, et al. . Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: the prospective COVAC-DM cohort study. Diabetes Obes Metab. (2022) 24:849–58. 10.1111/dom.14643 PubMed DOI PMC
Ou X, Jiang J, Lin B, Liu Q, Lin W, Chen G, et al. . Antibody responses to COVID-19 vaccination in people with obesity: a systematic review and meta-analysis. Influenza Other Respir Viruses. (2023) 17:e13078. 10.1111/irv.13078 PubMed DOI PMC
Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, et al. . Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. (2021) 75:435–8. 10.1016/j.jhep.2021.04.020 PubMed DOI PMC
Teeyapun N, Luangdilok S, Pakvisal N, Sainamthip P, Mingmalairak S, Poovorawan N, et al. . Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: a prospective, multicenter observational study. EClinicalMedicine. (2022) 52:101608. 10.1016/j.eclinm.2022.101608 PubMed DOI PMC
Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wörmann B, Turajlic S, et al. . COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. (2022) 19:385–401. 10.1038/s41571-022-00610-8 PubMed DOI PMC
Levine-Tiefenbrun M, Yelin I, Alapi H, Katz R, Herzel E, Kuint J, et al. . Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. (2021) 27:2108–10. 10.1038/s41591-021-01575-4 PubMed DOI
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. (2021) 27:1205–11. 10.1038/s41591-021-01377-8 PubMed DOI
Bar-On Bar-On YM. Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. . Protection against COVID-19 by BNT162b2 booster across age groups. N Engl J Med. (2021) 385:2421–30. 10.1056/NEJMoa2115926 PubMed DOI PMC
Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Vichaiwattana P, Thongmee T, et al. . Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study. Hum Vaccin Immunother. (2022) 18:2029111. 10.1080/21645515.2022.2029111 PubMed DOI PMC
Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T, et al. . Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine. (2022) 40:524–30. 10.1016/j.vaccine.2021.11.083 PubMed DOI PMC
Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, et al. . Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. (2022) 13:2670. 10.1038/s41467-022-30340-5 PubMed DOI PMC
Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, et al. . Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens. Int J Infect Dis. (2023) 126:64–72. 10.1016/j.ijid.2022.11.022 PubMed DOI PMC
Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, et al. . Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Vaccine. (2022) 40:5657–63. 10.1016/j.vaccine.2022.08.033 PubMed DOI PMC
Suntronwong N, Assawakosri S, Kanokudom S, Yorsaeng R, Auphimai C, Thongmee T, et al. . Strong correlations between the binding antibodies against wild-type and neutralizing antibodies against omicron BA1 and BA2 variants of SARS-CoV-2 in individuals following booster (Third-Dose) vaccination. Diagnostics (Basel). (2022) 12:1781. 10.3390/diagnostics12081781 PubMed DOI PMC
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. . Covid-19 vaccine effectiveness against the omicron (B11529) variant. N Engl J Med. (2022) 386:1532–46. 10.1056/NEJMoa2119451 PubMed DOI PMC
Kelly JD, Leonard S, Hoggatt KJ, Boscardin WJ, Lum EN, Moss-Vazquez TA, et al. . Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines. JAMA. (2022) 328:1427–1437. 10.1001/jama.2022.17985 PubMed DOI PMC
Tan SHX, Pung R, Wang LF, Lye DC, Ong B, Cook AR, et al. . Association of homologous and heterologous vaccine boosters with COVID-19 incidence and severity in Singapore. JAMA. (2022) 327:1181–2. 10.1001/jama.2022.1922 PubMed DOI PMC
